{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:16:37Z","timestamp":1789017397550,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T00:00:00Z","timestamp":1240963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["5P01CA68484"],"award-info":[{"award-number":["5P01CA68484"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Asparaginase, an agent used in the treatment of acute lymphoblastic leukemia (ALL), is associated with the development of pancreatitis. The clinical course and long\u2010term outcome of patients experiencing this complication has not been extensively detailed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>We reviewed the clinical course for all children with ALL diagnosed with pancreatitis at the Dana\u2010Farber Cancer Institute\/Children's Hospital Boston between 1987 and 2003. The outcome of these patients was compared with that of patients with ALL who did not experience pancreatitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010eight of 403 children (7%) were diagnosed with pancreatitis. Patients 10\u201318 years old at diagnosis had 2.4 times the risk of developing pancreatitis compared with younger patients. Pancreatitis typically occurred early in the course of therapy (median 4 weeks after first dose of asparaginase). Ninety\u2010three percent of affected patients were hospitalized and 57% received parenteral nutrition. No patient developed chronic sequelae or died as a result of pancreatitis. Sixteen (57%) patients were re\u2010treated with asparaginase, 10 of whom had another episode of pancreatitis. No significant differences in event\u2010free survival were observed when comparing patients with and without a history of pancreatitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Asparaginase\u2010associated pancreatitis was more common in older children, and caused significant acute morbidity. It tended to occur after the first few doses of asparaginase, suggesting a predisposition to this complication rather than a cumulative drug effect. Re\u2010treatment with asparaginase after an episode of pancreatitis was associated with a high risk of recurrent pancreatitis. Pediatr Blood Cancer 2009;53:162\u2013167. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.22076","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T18:01:26Z","timestamp":1241028086000},"page":"162-167","source":"Crossref","is-referenced-by-count":148,"title":["Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase\u2010associated pancreatitis"],"prefix":"10.1002","volume":"53","author":[{"given":"Susan L.","family":"Kearney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Dahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan D.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,29]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.127.6.1055"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.160.3827.533"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(69)90375-X"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197002)25:2<306::AID-CNCR2820250206>3.0.CO;2-H"},{"key":"e_1_2_5_6_2","first-page":"137","article-title":"L\u2010Asparaginase (L\u2010ASP) in advanced childhood leukemia: Comparative trial of drug schedules singly and in combination","author":"Rausen A","year":"1970","journal-title":"Proc Am Assn Cancer Res"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950030410"},{"issue":"11","key":"e_1_2_5_8_2","first-page":"5601","article-title":"Influence of intensive asparaginase in the treatment of childhood non\u2010T\u2010cell acute lymphoblastic leukemia","volume":"43","author":"Sallan SE","year":"1983","journal-title":"Cancer Res"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198609113151101"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.237"},{"issue":"4","key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.1994.12.4.740","article-title":"Treatment of childhood acute lymphoblastic leukemia: Results of Dana\u2010Farber Cancer Institute\/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85\u201001","volume":"12","author":"Schorin MA","year":"1994","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401980"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-027714"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196911062811902"},{"issue":"7","key":"e_1_2_5_16_2","first-page":"942","article-title":"L\u2010asparaginase in the treatment of neoplastic diseases in children","volume":"31","author":"Jaffe N","year":"1971","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_2_5_17_2","first-page":"9","article-title":"Evaluation of intramuscular versus intravenous administration of L\u2010asparaginase in childhood leukemia","volume":"1","author":"Nesbit M","year":"1979","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(200003)34:3<200::AID-MPO7>3.0.CO;2-T"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197409)34:3<780::AID-CNCR2820340338>3.0.CO;2-U"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21037"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb06336.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb00032.x"},{"issue":"1","key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-0038-1651179","article-title":"Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L\u2010asparaginase: A GIMEMA study","volume":"69","author":"Leone G","year":"1993","journal-title":"Thromb Haemost"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1986"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2734"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(72)80276-2"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197208)30:2<339::AID-CNCR2820300206>3.0.CO;2-P"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950020405"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.1886"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1155\/2001\/435746"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22076","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22076","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T11:13:09Z","timestamp":1696936389000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,29]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1002\/pbc.22076"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22076","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,29]]}}}